This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Radient Pharma Readies Onko-Sure Data

TUSTIN, Calif. (TheStreet) -- Here are some updates, observations and answers to common questions about Radient Pharmaceuticals (RPC) as the clock ticks down to the release of data from a clinical validation study of the company's cancer monitoring test Onko-Sure:

Is Onko-Sure more accurate than the carcinoembryonic antigen (CEA) test in monitoring colon cancer?

That's what Radient believes, especially in patients with early-stage colon cancer, which is why the company (and its retail investor fan base) is placing so much emphasis on data from this ongoing validation study. Results are expected before the end of the quarter, which is Thursday.

Both Onko-Sure and CEA are already cleared by the Food and Drug Administration as blood-based tests to monitor the progression of colon cancer. In order to show superiority of Onko-Sure over CEA, Radient purchased from the Mayo Clinic 976 blood samples taken from colon cancer patients in various stages of the disease.

The Mayo Clinic tested these samples using the CEA test, while Radient is testing the same samples using Onko-Sure. The results from the two tests will then be compared against each other. Radient is especially hopeful that Onko-Sure will prove to be more accurate than the CEA test in patients with early-stage colon cancer.

Wait! You just said the Mayo Clinic tested these samples using the CEA test, which means Mayo really is partnered with Radient on this Onko-Sure test! You're a liar!

Wow, take off the tin-foil hat. Radient bought colon cancer blood samples from Mayo tested with CEA. That's it. Radient is conducting the actual validation study on its own. Recall Mayo's public statement regarding the Onko-Sure study:

"Mayo is not engaged in clinical studies with Radient and does not have a partnership agreement with Radient."

Think of this controvery another way: If Mayo were working with Radient on this Onko-Sure study (as Radient has claimed), then why isn't Mayo testing the colon cancer blood samples with CEA and Onko-Sure? Wouldn't it make more sense for Mayo, one of the most prestigious and independent research hospitals in the country, to conduct all the testing? It would certainly lend additional credibility to the results, whatever they might be.

But Mayo isn't doing all the testing. Instead, Radient ran the Onko-Sure tests on its own, which is not exactly the most unbiased way of conducting a clinical trial, even if a third-party statistical group is expected to tabulate the results.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs